Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.74 |
| ▸ | LPAR1 | Q92633 | 10/20 | 0.74 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.55 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.54 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.52 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261983 | 1.00 | LPAR3 (0.74) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL1534300 | 1.00 | LPAR3 (0.74) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30443625 | 0.98 | LPAR3 (0.77) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL6225095 | 0.98 | LPAR3 (0.77) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30556755 | 0.98 | LPAR3 (0.77) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| Glycerin SCHEMBL27912356 | 0.93 | LPAR3 (0.69) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| Monoethanolamine SCHEMBL27933634 | 0.91 | LPAR3 (0.68) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30137737 | 0.90 | LPAR1 (0.66) | LPAR3LPAR1LPAR2S1PR1ENPP2 | |
| SCHEMBL7212085 | 0.88 | LPAR5 (0.69) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL2732573 | 0.87 | LPAR3 (0.97) | LPAR3LPAR1LPAR2LPAR5LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117751106-A | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2H-pyranylacetic acid compounds as LPA antagonists | 唯久生物技术(苏州)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20090317858-A1 | CELLULAR ASSAYS FOR SIGNALING RECEPTORS | Life Technologies Corporation (US) | 2009-12-24 | — | — | US | disclosed |
| US-20070218456-A1 | CELLULAR ASSAYS FOR SIGNALING RECEPTORS | INVITROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | LPAR3 7/4885LPAR1 6/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.